ORGANOGENESIS

Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers

July 27, 2026

CANTON, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced published results from a prospective, multicenter, randomized controlled trial (RCT) evaluating Affinity plus standard of care (SoC) compared to SoC alone in the management of complex venous leg ulcers (VLUs). The results were published in the *Journal of Wound Care* demonstrating statistically significant improvements in wound closure at weeks 12 and 16 for the Affinity + SoC group across two wound duration strata studied, providing compelling new peer-reviewed evidence for one of the most difficult-to-treat wound populations in chronic wound care.

"These clinically meaningful results demonstrate the value of Affinity as a protective barrier in challenging VLUs," said Patrick Bilbo, Chief Operating Officer of Organogenesis. "Paired with our DFU data, this strengthens the case that Affinity delivers meaningful outcomes for the patients who need it most."

The 206-patient trial, which randomized 1:1 to Affinity + SoC or SoC alone, followed patients for 24 weeks after a four-week run-in period. Across both baseline wound duration (BWD) strata, which included wounds present for more than 6 months and wounds present for more than 24 months, the Affinity + SoC group achieved significantly higher rates of wound closure than SoC alone at weeks 12 and 16 ($p<0.05$).

This trial builds on the growing body of evidence for Affinity, now spanning RCTs and real-world data, across multiple chronic wound indications. These findings reinforce the benefit of Affinity in the hardest-to-heal wounds, the population that drives the greatest clinical burden and cost in VLU treatment. As VLU costs continue to grow, particularly within the Medicare population, these results present a meaningful step forward for patients, clinicians, and payers. This VLU data set complements existing Affinity evidence in diabetic foot ulcers (DFUs), reinforcing the clinical and economic rationale for expanded coverage across two of the most prevalent and costly chronic wound types.

About Affinity

Affinity is the only hypothermically stored human placental allograft composed of fresh, unaltered amniotic membrane that retains its native extracellular matrix scaffold and living cells for use as a protective barrier. Never dehydrated or frozen, Affinity is minimally manipulated, aseptically processed, and uniquely preserved in a fresh state. Affinity is intended for use as a protective barrier in the management of acute and chronic wounds.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the Advanced Wound Care and Surgical and Sports Medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Forward-Looking Statements

Contacts Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@westwicke.com Press and Media Inquiries: Cheston Turbyfill cturbyfill@organo.com